Interferon-alpha: a therapeutic target in systemic lupus erythematosus

Area of Science:

• Immunology
• Rheumatology

Background:

• Elevated interferon (IFN)-alpha is historically associated with disease activity in systemic lupus erythematosus (SLE).
• Accumulating data strongly support broad type I IFN pathway activation in lupus patients.
• IFN pathway activation correlates with significant clinical manifestations and increased disease activity in SLE.

Purpose of the Study:

• To summarize the current understanding of the type I IFN pathway in SLE.
• To highlight the role of RNA-containing immune complexes and Toll-like receptor activation.
• To discuss the translational potential of IFN pathway research for improved SLE patient care.

Main Methods:

• Review of existing literature on IFN pathway activation in SLE.
• Analysis of associations between IFN pathway activation, clinical manifestations, and autoantibodies.
• Examination of progress in lupus genetics related to IFN production and response.

Main Results:

• Strong evidence supports type I IFN pathway activation in SLE patients, linked to disease activity and specific autoantibodies.
• Toll-like receptor activation by RNA-containing immune complexes amplifies innate immune and IFN pathway activation.
• Lupus genetics research is identifying variants functionally related to IFN pathways.

Conclusions:

• The type I IFN pathway is a significant factor in SLE pathogenesis and disease activity.
• Understanding IFN pathway activation opens avenues for novel SLE biomarkers and therapeutics.
• Clinical trials targeting IFN-alpha are underway, with other approaches potentially following.